rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-443-446rsp-2934Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESИммуноопосредованные нежелательные ревматологические реакции как последствия применения ингибиторов иммунных контрольных точекImmune-mediated adverse rheumatic reactions following administration of immune checkpoint inhibitorshttps://orcid.org/0000-0003-3181-5272МеньшиковаИ. В.MenshikovaI. V.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2 Moscow 119991

ivmenshikova@mail.ruhttps://orcid.org/0000-0002-8871-650XСтрогоноваВ. В.StrogonovaV. V.

119991, Москва, ул. Трубецкая, 8, стр. 2

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University, MOH (Sechenov University)Russian Federation202004092020584443446Copyright © Меньшикова И.В., Строгонова В.В., 20202020Меньшикова И.В., Строгонова В.В.Menshikova I.V., Strogonova V.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2934

Применение ингибиторов иммунных контрольных точек (ИКТ) открывает новые перспективы в лечении злокачественных новообразований, но вместе с тем такое лечение приводит к развитию иммуноопосредованных неблагоприятных реакций (ИОНР), которые ограничивают клиническое применение этих препаратов. ИОНР могут поражать практически любую систему, включая эндокринную, дыхательную, пищеварительную, нервную, а также кожу и другие органы. Чаще всего ИОНР характеризуются умеренной степенью тяжести, однако у 2% пациентов возникают летальные осложнения. Особый интерес для клиницистов представляют ревматические ИОНР, которые могут возникать на разных сроках и сохраняются после отмены ингибиторов ИКТ. В обзоре рассматривается распространенность, клинические характеристики и подходы к лечению ревматических ИОНР. 

Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including the endocrine, respiratory, digestive, nervous, other organs and the skin. Most often irAEs are characterized by moderate degree of severity, but complications are fatal in 2% of patients.The nature of irAEs significantly differs from the adverse reactions associated with use of standard chemotherapeutic agents, which usually cause immunosuppression (due to neutropenia). Of particular interest to clinicians are rheumatic irAEs, which can occur at any time after treatment and tend to persist even after ICIs discontinuation. This review analyzes the prevalence, clinical characteristics, and approaches to treatment of rheumatic irAEs. 

ингибиторы иммунных контрольных точекиммуноопосредованные неблагоприятные реакцииантиген-4 цитотоксических Т-лимфоцитов (CTLA-4)белок программированной гибели клеток (PD-1)immune checkpoint inhibitorsimmune-related adverse reactionscytotoxic T lymphocyte antigen-4 антиген-4 (CTLA-4)programmed cell death protein 1 (PD-1)Исследование поддержано «Проектом повышения конкурентоспособности ведущих российских университетов среди ведущих мировых научно-образовательных центров».ReferencesKostine M, Finckh A, Bingham CO III, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors [published online April 23, 2020]. Ann Rheum Dis. doi:10.1136/annrheumdis-2020-217139Kostine M, Finckh A, Bingham CO III, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors [published online April 23, 2020]. Ann Rheum Dis. doi:10.1136/annrheumdis-2020-217139Реутова ЕВ, Лактионов КП, Бредер ВВ, Саранцева КА, Окружнова МА, Перегудова МВ. Иммуноопосредованные нежелательные явления, связанные с лечением препаратами, блокирующими контрольные точки Т-лимфоцитов. Злокачественные опухоли. 2016;4(20):68-76. doi:10.18027/2224-5057-2016-4-68-76Reutova EV, Laktionov KP, Breder VV, Sarantseva KA, Okruzhnova MA, Peregudova MV. Immune-mediated adverse events associated with immune checkpoint inhibitors therapy. Zlokachestvenyye opukholi = Malignant tumours Journal. 2016; 4:68-76. (In Russ.) doi:10.18027/2224-5057-2016-4-68-76Kostine M, Cappelli LC, Calabrese C, et al. Addressing immunerelated adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis. 2019; 78(6):860-862. doi:10.1136/annrheumdis-2018-214748Kostine M, Cappelli LC, Calabrese C, et al. Addressing immunerelated adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann Rheum Dis. 2019; 78(6):860-862. doi:10.1136/annrheumdis-2018-214748Bilbao LS, González-Mazón I, Martín-Varillas JL, et al. Immune-related adverse events associated with immunotherapy. Long-term follow-up of 102 patients from a referral single center. Ann Rheum Dis. 2019;78(2):1002. doi:10.1136/annrheumdis-2019-eular.7141Bilbao LS, González-Mazón I, Martín-Varillas JL, et al. Immune-related adverse events associated with immunotherapy. Long-term follow-up of 102 patients from a referral single center. Ann Rheum Dis. 2019;78(2):1002. doi:10.1136/annrheumdis-2019-eular.7141Cappelli LC, Shah AA, Bingham CO. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Amer. 2017; 43(1):65-78. doi:10.1016/j.rdc.2016.09.007Cappelli LC, Shah AA, Bingham CO. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheum Dis Clin North Amer. 2017; 43(1):65-78. doi:10.1016/j.rdc.2016.09.007Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017; 3(1):1–5. doi:10.1136/rmdopen-2016-000412Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immunerelated adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017; 3(1):1–5. doi:10.1136/rmdopen-2016-000412Насонов ЕЛ. Ингибиция иммунных контрольных точек и аутоиммунитет: ревматологические проблемы. Научно-практическая ревматология. 2018; 56(1):5-9. [Nasonov EL. Iimmune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018; 56(1):5-9. (In Russ.). doi:10.14412/1995-4484-2018-5-9Nasonov EL. Iimmune checkpoint inhibition and autoimmunity: rheumatological problems. Nauchno-Prakticheskaya Revmatologiya= Rheumatology Science and Practice. 2018; 56(1):5-9. (In Russ.). doi:10.14412/1995-4484-2018-5-9Dhenin A, Samartzi V, Lejeune S, et al. Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ. 2019; 12(6):1–7. doi:10.1136/bcr-2018-229149Dhenin A, Samartzi V, Lejeune S, et al. Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ. 2019; 12(6):1–7. doi:10.1136/bcr-2018-229149Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis Rheumatol. 2017; 69(4):687-699. doi:10.1002/art.40043Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis Rheumatol. 2017; 69(4):687-699. doi:10.1002/art.40043Лепик КВ. Ингибиторы иммунных контрольных точек в терапии лимфом. Клиническая онкогематология. 2018;11(4):303–312. doi:10.21320/2500-2139-2018-11-4-303-312.Lepik KV. Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Klinicheskaya onkogematologiya = Clinical Oncohematology Journal. 2018;11(4):303–312. (In Russ.). doi:10.21320/2500-2139-2018-11-4-303-312Rapoport BL. Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors. Frontiers in Oncology. 2019;19(9):1–3. doi:10.3389/fonc.2019.00365Rapoport BL. Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors. Frontiers in Oncology. 2019;19(9):1–3. doi:10.3389/fonc.2019.00365Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Med. 2019;8(8):4023-4031. doi:10.1002/cam4.2280Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Med. 2019;8(8):4023-4031. doi:10.1002/cam4.2280Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Ann Rheum Dis. 2019;78(6):e58. doi:10.1136/annrheumdis-2018-213415Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Manolios N, Schrieber L. Checkpoint inhibitors and arthritis. Ann Rheum Dis. 2019;78(6):e58. doi:10.1136/annrheumdis-2018-213415Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist. 2017;22(6):627-630. doi:10.1634/ theoncologist.2016-0390Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist. 2017;22(6):627-630. doi:10.1634/ theoncologist.2016-0390Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393-398. doi:10.1136/annrheumdis-2017-212257Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393-398. doi:10.1136/annrheumdis-2017-212257Sapalidis K, Kosmidis C, Michalopoulos N, et al. Psoriatic arthritis due to nivolumab administration a case report and review of the literature. Respir Med Case Rep. 2018;23:182-187. doi:10.1016/j.rmcr.2018.03.001Sapalidis K, Kosmidis C, Michalopoulos N, et al. Psoriatic arthritis due to nivolumab administration a case report and review of the literature. Respir Med Case Rep. 2018;23:182-187. doi:10.1016/j.rmcr.2018.03.001Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer [published correction appears in Neurology. 2019;93(6):280]. Neurology. 2018;91(10):e985-e994. doi:10.1212/WNL.0000000000006124Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer [published correction appears in Neurology. 2019;93(6):280]. Neurology. 2018;91(10):e985-e994. doi:10.1212/WNL.0000000000006124Calabrese C, Cappelli LC, Kostine M, et al. Polymyalgia rheumatica-like syndrome fron checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5:e000906 doi:10.1136/rmdopen-2019-000906.Calabrese C, Cappelli LC, Kostine M, et al. Polymyalgia rheumatica-like syndrome fron checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5:e000906 doi:10.1136/rmdopen-2019-000906.Kostine M, Richez C, Schaeverbeke T. Response to: ‘Druginduced lupus erythematosus following immunotherapy with antiprogrammed death-(ligand) 1’ by Michot et al and ‘Checkpoint inhibitor-associated immune arthritis’ by Arnaud et al. Ann Rheum Dis. 2019;78(7):69. doi:10.1136/annrheumdis-2018-213691Kostine M, Richez C, Schaeverbeke T. Response to: ‘Druginduced lupus erythematosus following immunotherapy with antiprogrammed death-(ligand) 1’ by Michot et al and ‘Checkpoint inhibitor-associated immune arthritis’ by Arnaud et al. Ann Rheum Dis. 2019;78(7):69. doi:10.1136/annrheumdis-2018-213691Tison A, Quere G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoinnune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100-2111. doi:10.1002/art.41068Tison A, Quere G, Misery L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoinnune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100-2111. doi:10.1002/art.41068Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2019;5(9):1310-1317. doi:10.1001/jamaoncol.2019.1022Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2019;5(9):1310-1317. doi:10.1001/jamaoncol.2019.1022Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017;22(10):1232-1237. doi:10.1634/theoncologist.2017-0133Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist. 2017;22(10):1232-1237. doi:10.1634/theoncologist.2017-0133Gordon R, Kasler MK, Stasi K, et al. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management. Clin J Oncol Nurs. 2017;21(2):45-52. doi:10.1188/17.CJON.S2.45-52Gordon R, Kasler MK, Stasi K, et al. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management. Clin J Oncol Nurs. 2017;21(2):45-52. doi:10.1188/17.CJON.S2.45-52Arnaud L, Lebrun-Vignes B, Salem J. Checkpoint inhibitorassociated immune arthritis. Ann Rheum Dis. 2019; 78(7):68. doi:10.1136/annrheumdis-2018-213470Arnaud L, Lebrun-Vignes B, Salem J. Checkpoint inhibitorassociated immune arthritis. Ann Rheum Dis. 2019; 78(7):68. doi:10.1136/annrheumdis-2018-213470

The authors declare that there are no conflicts of interest present.